These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 15929133)

  • 1. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
    Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
    Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
    Ballerini A; Moro F; Nerini IF; Marzo CM; Di Clemente A; Ferrari M; D'Incalci M; Biondi A; Colombini A; Conter V; Porcu L; Cervo L; Rizzari C; Zucchetti M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1267-1271. PubMed ID: 28424964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
    Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
    Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
    Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
    Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
    Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
    Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
    Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
    Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
    In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.